ASX - Delayed Quote • AUD
Biotron Limited (BIT.AX)
At close: 3:55 PM GMT+10
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. | MD & Executive Director | 387.43k | -- | -- |
| Mr. Peter James Nightingale B.Econ, CA | Company Secretary | 120k | -- | 1957 |
| Dr. Stephen L. Becker M.D. | Chief Medical Officer | -- | -- | -- |
Biotron Limited
56 Delhi Road
Suite 3.3 North Ryde
Sydney, NSW 2113
Australia
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.
Corporate Governance
Biotron Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
Recent Events Information Not Available
Upcoming Events
Feb 27, 2024
Biotron Limited Earnings Call